OBJECTIVES The purpose of this study was to investigate the effects of mineralocorticoid receptor antagonists (MRAs) on systolic blood pressure (SBP) and outcomes according to baseline SBP in patients with heart failure with reduced ejection fraction (HFrEF).
A lthough mineralocorticoid receptor antagonist (MRA) therapy has been shown in randomized trials to reduce mortality in patients with heart failure and reduced ejection fraction (HFrEF), MRA therapy is greatly underused in everyday practice (1, 2) . Despite the evidence from clinical trials and a Class I, Level of Evidence: A recommendation in guidelines, registry data from different regions of the world consistently show lower use of MRA drugs than of angiotensin-converting enzyme (ACE) inhibitors/angiotensin receptor blockers (ARBs), or beta-blockers (3, 4) . Hyperkalemia is a well-recognized concern, leading to underprescription of MRA drugs, but physicians also report an unwillingness to prescribe these medications in patients with low blood pressure (5) . The findings of the recent PATHWAY-2 (Prevention And Treatment of Hypertension With Algorithm based therapY) trial seem to have led to the perception that MRAs are powerful antihypertensive agents and amplified the concern about hypotension in patients with HFrEF (6) . In PATHWAY-2, spironolactone therapy started at 25 mg daily and force-titrated to 50 mg reduced home systolic blood pressure (SBP) by a mean of 8.70 mm Hg (95% confidence interval [CI]: À9.72 to À7.69; p < 0.0001) compared with placebo and was more effective than alternative fourth-line drugs (bisoprolol or doxazosin) in patients with resistant hypertension already treated with an ACE inhibitor/ARB, a calcium channel blocker, and a thiazide or thiazidelike diuretic.
To determine whether physicians should be concerned about MRA-induced hypotension in patients with HFrEF, this study analyzed the effect of MRA therapy on blood pressure and outcomes, according to baseline blood pressure in the 2 major randomized placebo-controlled trials using drugs in this class
(spironolactone and eplerenone) in patients with
HFrEF.
METHODS
DETAILS OF TRIALS INCLUDED. The design, baseline findings, and primary results of the 2 trials have been reported previously in detail (1, 2, 7, 8 NYHA functional class <0.001 MRA ¼ mineralocorticoid receptor antagonist; SBP ¼ systolic blood pressure. (Figures 2 and 3) . The benefit of MRA therapy was consistent across SBP categories, and there was Figure 3 ). Similar findings were observed examining pretreatment SBP as a continuous variable (Online Figure S1 ). Elevation of creatinine and potassium concentrations was more common in the MRA than in the placebo group (Table 4) , although the rate of these adverse effects did not differ greatly across SBP categories (Online Table S1 ). Abbreviations as in Figure 1 . Table S1 ). The rates of discontinuation between the placebo and MRA groups did not differ across SBP categories. (19) .
DISCUSSION
In the present study, patients in the lowest SBP group had a similar relative risk reduction in all outcomes of interest with MRA treatment, as patients with a higher SBP. This is relevant because many physicians are concerned about prescribing drugs with a hypotensive effect to heart failure patients with low blood pressure, potentially depriving them of the mortality benefit of these treatments (20 Tables 1 and 2 .
Abbreviations as in
Serenelli et al. Rates of use of beta-blocker therapy in real world registries are approximately 80%, but no evidence was found that the blood pressure-lowering effects of MRA were different in the 2 trials, where beta-blocker use was different at baseline. The present results would therefore be applicable to the wider population where rates of beta-blocker use lie between these 2 extremes.
Finally, the effects of eplerenone, according to baseline SBP at or above versus below the median value (123 mm Hg), have previously been described in EMPHASIS-HF, although only the primary composite outcome was reported (21) . 
CONCLUSIONS

